Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Quillivant XR

- PMLiVE

FDA considers new safety warnings for Pfizer’s JAK inhibitor Xeljanz

Post-marketing study shows increased risk of serious heart-related problems and cancer with Xeljanz

EU flag

EU orders another 300 million doses of Pfizer/BioNTech’s COVID-19 vaccine

Pfizer/BioNTech's has an existing agreement with the EU for an initial 300 million doses

- PMLiVE

Pfizer aims for $15bn in 2021 COVID-19 vaccine sales

Current estimate is based on already agreed contracts

- PMLiVE

UK launches world-first COVID-19 study evaluating a mixed-vaccine regimen

Participants could receive AZ/Oxford University's vaccine for their first dose and Pfizer/BioNTech's vaccine for their second

- PMLiVE

Novartis, Bayer announce separate agreements to bolster COVID-19 vaccine manufacturing

Novartis will help manufacture Pfizer/BioNTech's vaccine and Bayer will do the same for CureVac's vaccine

- PMLiVE

South Africa COVID-19 variant ‘unlikely’ to reduce efficacy of Pfizer/BioNTech jab

Lab study tested blood samples of vaccinated individuals against key virus mutations

- PMLiVE

Sanofi will provide manufacturing support for Pfizer/BioNTech’s COVID-19 vaccine

Sanofi is aiming to provide 100 million doses of the vaccine by the end of the year

- PMLiVE

Pfizer/BioNTech to develop a booster dose for their COVID-19 vaccine

Boosters will be designed to protect against new variants

- PMLiVE

Moderna’s COVID-19 vaccine appears effective against UK and South Africa variants

However, vaccine has a six-fold reduction in neutralising antibodies against SA strain

- PMLiVE

Pfizer/BioNTech reach vaccine supply agreement with COVAX

Up to 40 million doses will be supplied to the international vaccine-sharing facility

- PMLiVE

Pfizer, BioNTech temporarily slow down shipments of COVID-19 vaccine to EU

'Temporary' reduction comes as companies bolster production capacity for the year

- PMLiVE

Merck wins speedy FDA review for 15-valent pneumococcal vaccine

Pfizer's rival 20-valent candidate was granted priority review in December 2020

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links